

Lori S Muffly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7127299/publications.pdf>

Version: 2024-02-01

133
papers

2,619
citations

257450

24
h-index

214800

47
g-index

136
all docs

136
docs citations

136
times ranked

3446
citing authors

#	ARTICLE	IF	CITATIONS
1	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	30.7	273
2	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <i>Haematologica</i> , 2014, 99, 1373-1379.	3.5	213
3	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	1.4	210
4	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 2105-2119.	1.6	155
5	Evaluation of Breast Tumor Response to Neoadjuvant Chemotherapy with Tomographic Diffuse Optical Spectroscopy: Case Studies of Tumor Region-of-Interest Changes. <i>Radiology</i> , 2009, 252, 551-560.	7.3	111
6	Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 429-434.	2.0	111
7	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 725.	7.1	111
8	Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience. <i>Breast Cancer Research</i> , 2013, 15, R35.	5.0	98
9	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 143-155.	5.2	92
10	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, 356-368.	1.6	79
11	Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. <i>Cancer</i> , 2016, 122, 954-961.	4.1	60
12	Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study. <i>Blood Advances</i> , 2018, 2, 895-903.	5.2	55
13	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	1.4	51
14	Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. <i>JCI Insight</i> , 2019, 4, .	5.0	46
15	Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2293-2300.	4.3	45
16	Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. <i>Blood</i> , 2018, 132, 490-490.	1.4	43
17	Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 744-744.	1.4	42
18	Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. <i>Cancer</i> , 2018, 124, 1938-1945.	4.1	40

#	ARTICLE	IF	CITATIONS
19	Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2018, 132, 898-898.	1.4	40
20	Adoption of pediatricâ€­inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A populationâ€­based study. <i>Cancer</i> , 2017, 123, 122-130.	4.1	38
21	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
22	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
23	The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2193.	4.1	30
24	Treatment of young adults with Philadelphiaâ€­negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyperâ€­CVAD vs. pediatricâ€­inspired regimens. <i>American Journal of Hematology</i> , 2018, 93, 1254-1266.	4.1	29
25	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 4465-4475.	5.2	28
26	Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 681-690.	5.2	27
27	Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 503-506.	1.3	26
28	Advance Directive Utilization Is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1035-1040.	2.0	25
29	Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4474-4482.	5.2	25
30	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
31	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
32	Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 3147-3151.	5.2	21
33	End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, 3023-3030.	1.6	17
34	Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 17-23.	2.5	16
35	Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1608-1618.	5.2	15
36	Late Effects in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa025.	2.9	14

#	ARTICLE	IF	CITATIONS
37	Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia. <i>JCO Oncology Practice</i> , 2020, 16, e1120-e1133.	2.9	13
38	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1744-1748.	2.0	12
39	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. <i>Blood Advances</i> , 2019, 3, 2454-2464.	5.2	12
40	Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 3091-3093.	2.4	11
41	Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults: a population-based study. <i>International Journal of Epidemiology</i> , 2021, 50, 663-674.	1.9	11
42	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 215.e1-215.e10.	1.2	11
43	Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e328-e332.	2.0	10
44	Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. <i>Leukemia and Lymphoma</i> , 2021, 62, 257-263.	1.3	10
45	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.	1.2	10
46	Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 32-33.	1.4	10
47	Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4085-4092.	5.2	10
48	Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. <i>Blood Advances</i> , 2021, 5, 1757-1759.	5.2	9
49	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2664-2671.	2.4	9
50	Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy. <i>Translational Pediatrics</i> , 2012, 1, 120-2.	1.2	9
51	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. <i>Blood Advances</i> , 2017, 1, 1347-1357.	5.2	8
52	Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California. <i>Journal of Oncology Practice</i> , 2019, 15, e316-e327.	2.5	8
53	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 368-375.	2.4	8
54	Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	8

#	ARTICLE	IF	CITATIONS
55	Hematopoietic Cell Transplantation in Young Adult Acute Lymphoblastic Leukemia: A United States Population-Level Analysis. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 254-261.	1.3	7
56	Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020. <i>Seminars in Hematology</i> , 2020, 57, 137-141.	3.4	7
57	Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 166-171.	1.3	6
58	Management of acute lymphoblastic leukemia in young adults. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 138-146.	0.3	6
59	Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. <i>Expert Review of Hematology</i> , 2019, 12, 99-106.	2.2	5
60	Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 590.e1-590.e8.	1.2	5
61	Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era. <i>Cancer</i> , 2022, 128, 139-149.	4.1	5
62	Financial toxicity in children, adolescent, and young adult cancer patients and their families: A large national registry analysis from the family reach foundation.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6615-6615.	1.6	5
63	A Three-Step Letter Advance Directive Procedure to Facilitate Patient-Proxy Alignment in Advance Care Planning. <i>Journal of Palliative Medicine</i> , 2018, 21, 1749-1754.	1.1	4
64	Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 405.e1-405.e6.	1.2	4
65	Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. <i>Blood</i> , 2020, 136, 47-48.	1.4	4
66	Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>JCO Oncology Practice</i> , 2020, 16, 231-238.	2.9	4
67	Treating the younger adult with acute lymphoblastic leukemia. <i>Clinical Practice (London, England)</i> , 2012, 9, 439-449.	0.1	4
68	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2019, 134, 2022-2022.	1.4	4
69	Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 112.e1-112.e9.	1.2	4
70	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	1.4	4
71	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. <i>Blood</i> , 2020, 136, 32-33.	1.4	4
72	The overlooked COST of multiple myeloma. <i>Lancet Haematology</i> , 2015, 2, e394-e395.	4.6	3

#	ARTICLE	IF	CITATIONS
73	Coordination of Care in Survivorship After Treatment of Hematological Malignanciesâ€”The Journey is Not Over Yet. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 317-323.	2.3	3
74	Healthcare Utilization is High in Adult Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1659-1665.	2.0	3
75	Routine use of gemtuzumab ozogamicin in 7â€”based inductions for all â€”non-adverseâ€™ risk AML. <i>Leukemia and Lymphoma</i> , 2021, 62, 1510-1513.	1.3	3
76	Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8026-8026.	1.6	3
77	Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	3
78	Prognosis in diffuse large Bâ€”cell lymphoma. <i>Cancer</i> , 2013, 119, 1129-1131.	4.1	2
79	Patient Selection for Allogeneic Hematopoietic Cell Transplantation (HCT): the Evolution of HCT Risk Assessment. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 28-34.	2.3	2
80	Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California. <i>Leukemia and Lymphoma</i> , 2018, 59, 2482-2484.	1.3	2
81	Calcineurin-inhibitor induced pain syndrome after stem cell transplant. <i>Leukemia and Lymphoma</i> , 2020, 61, 2230-2233.	1.3	2
82	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. <i>Blood</i> , 2012, 120, 2728-2728.	1.4	2
83	Symptom burdens and coping strategies in adolescent and young adult (AYA) cancer survivors with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 256-256.	1.6	2
84	Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. <i>Blood</i> , 2021, 138, 3885-3885.	1.4	2
85	Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. <i>Blood</i> , 2021, 138, 98-98.	1.4	2
86	Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 584-594.	3.8	2
87	Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 516-527.	1.3	1
88	Minimal Residual Disease Monitoring of Acute Lymphoblastic Leukemia by High-Throughput Sequencing of the Peripheral Blood: Case Examples and Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S53-S55.	0.4	1
89	Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. <i>Blood Advances</i> , 2018, 2, 1547-1550.	5.2	1
90	Another reason to encourage psychosocial risk assessment in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1416-1417.	2.4	1

#	ARTICLE	IF	CITATIONS
91	Transplant for Acute Myeloid Leukemia in Patients Aged 70 Years and Older: Optimism and Opportunity. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e301-e302.	2.0	1
92	How I Approach the Patient Who Has MRD or Relapse After Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S32-S33.	0.4	1
93	Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 187-193.	2.3	1
94	Poster: CT-436: Chimeric Antigen Receptor-T Cell Therapy (CAR-T) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Systematic Review and Meta-Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S258.	0.4	1
95	Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012, 120, 3535-3535.	1.4	1
96	Suffering Before The Cure: Evaluation Of Psychological Morbidities In Adolescents and Young Adults With Hematologic Malignancies In Early Survivorship. <i>Blood</i> , 2013, 122, 771-771.	1.4	1
97	Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. <i>Blood</i> , 2015, 126, 3232-3232.	1.4	1
98	Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4615-4615.	1.4	1
99	Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR-T therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7552-7552.	1.6	1
100	Integrating cancer survivorship care into allogeneic BMT recovery.. <i>Journal of Clinical Oncology</i> , 2017, 35, 39-39.	1.6	1
101	Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon?. <i>Blood Reviews</i> , 2022, 52, 100892.	5.7	1
102	Medical Conditions Among Survivors of Adolescent and Young Adult Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 839-839.	1.4	1
103	Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7561-7561.	1.6	1
104	Delays in diagnosis in young patients with leukemia and lymphoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18138-e18138.	1.6	1
105	Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Blood</i> , 2021, 138, 3043-3043.	1.4	1
106	Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML. <i>Blood</i> , 2020, 136, 36-37.	1.4	1
107	Disparities in the Use of Allogeneic Hematopoietic Stem Cell Transplant Among Children, Adolescents, and Young Adults with Acute Leukemia in California. <i>Blood</i> , 2020, 136, 4-5.	1.4	1
108	My Patient, the Superhero. <i>Journal of Clinical Oncology</i> , 2017, 35, 1368-1369.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Acute leukemia in a patient with 15q overgrowth syndrome. American Journal of Medical Genetics, Part A, 2019, 179, 1025-1029.	1.2	0
110	Does Treatment Setting Matter? Evaluating Resource Utilization for Adolescents Treated in Pediatric vs Adult Cancer Institutions. Journal of the National Cancer Institute, 2019, 111, 224-225.	6.3	0
111	Access to specialized care and outcomes in adults with acute leukemias. Blood Advances, 2020, 4, 1538-1538.	5.2	0
112	Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplantation Recipients. Transplantation and Cellular Therapy, 2021, 27, 615.e1-615.e7.	1.2	0
113	Measurable Residual Disease in Acute Lymphoblastic Leukemia: Optimization and Innovation in 2021 and Beyond. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S85-S87.	0.4	0
114	Pretransplant Assessment for Hematopoietic Cell Transplantation Recipients and Donors. , 2021, , 55-72.		0
115	Uptake of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists treating adolescent and young adults (AYA): A population based analysis across Northern California.. Journal of Clinical Oncology, 2016, 34, 7031-7031.	1.6	0
116	Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.. Journal of Clinical Oncology, 2016, 34, 7046-7046.	1.6	0
117	Death anxiety, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship.. Journal of Clinical Oncology, 2016, 34, 10073-10073.	1.6	0
118	Adolescent and Young Adult Oncology Patients with Acute Lymphoblastic Leukemia: Shifting Location of Care over Time. Blood, 2016, 128, 2375-2375.	1.4	0
119	Rate of Rise of EBV Viral Load By Quantitative PCR after Allogeneic Transplantation Correlates with PTLD Facilitates Timely Institution of Rituximab. Blood, 2016, 128, 4609-4609.	1.4	0
120	Improved survival among children and adolescent and young adults with acute lymphoblastic leukemia (ALL) treated at specialized cancer centers in California.. Journal of Clinical Oncology, 2018, 36, 10502-10502.	1.6	0
121	Health Care Utilization Is High Amongst Adults Who Relapse Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 4778-4778.	1.4	0
122	Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2018, 132, 252-252.	1.4	0
123	Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data. Blood, 2021, 138, 337-337.	1.4	0
124	Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors. Blood, 2021, 138, 1819-1819.	1.4	0
125	Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation. Blood, 2020, 136, 33-34.	1.4	0
126	Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis. Blood, 2020, 136, 48-49.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma. Blood, 2020, 136, 11-12.	1.4	0
128	Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant. Blood, 2020, 136, 22-23.	1.4	0
129	Intensity of Front-Line Regimen Is Associated with Admissions, in-Hospital Days, and Discharge Destination in Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis. Blood, 2020, 136, 29-29.	1.4	0
130	Treatment Patterns, Type of Front-Line Regimen, and Outcomes Among Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis in the Modern Era. Blood, 2020, 136, 15-16.	1.4	0
131	Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 9, 1-16.	0.3	0
132	Assessment of measurable residual disease (MRD) in adult patients with acute lymphocytic leukemia: best use and a case report. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 9, 10-14.	0.3	0
133	Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Current Oncology Reports, 2022, , 1.	4.0	0